Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 trial of HRS9531 in patients with atherosclerotic cardiovascular disease
CTR20261494Phase 3Active
- Sponsor
- Fujian Shengdi Pharmaceuticals
- Start
- May 2026
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
A Phase 3 trial of HRS9531 in atherosclerotic disease, sponsored by Fujian Shengdi Pharmaceuticals. Started May 2026; status: active.
02
Drugs
HRS9531
03
Conditions
atherosclerotic disease
Beyond the preview
Go deeper on CTR20261494.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20261494.